Small interfering RNA (siRNA) shows great promise in cancer therapy, but its effectiveness in vivo still remains a crucial issue for its transition into the clinics. Although the successful use of polyethylene glycol (PEG)ylated lipidic delivery systems have already been reported, most of the formulation procedures used are labour intensive and also result in unstable end products. We have previously developed a simple yet efficient hydration-of-freeze-dried-matrix (HFDM) method to entrap siRNA within lipid particles, in which the products exhibited superior stability. Here, we show that these HFDM-formulated particles are stable in the presence of serum and can deliver siRNA efficiently to tumours after intravenous administration. Using these particles, around 50% knockdown of the target gene expression was observed in tumours. With the use of siRNA targeting the E6/7 oncogenes expressed in cervical cancer, we showed a 50% reduction in tumour size. This level of tumour growth suppression was comparable to that achieved from cisplatin at the clinically used dose. Overall, our results demonstrate the feasibility of using HFDM-formulated particles to systematically administer E6/7-targeted siRNA for cervical cancer treatment. The simplicity of preparation procedure along with superior product stability obtained from our method offers an innovative approach for the in vivo delivery of siRNA.
INTRODUCTION
Cancer formation is the result of the accumulation of numerous genetic and epigenetic changes, giving rise to cells with enhanced growth and survival characteristics. Typically, these changes result in the overexpression of oncogenes, making the selective targeting of these genes an attractive means to treat cancer. This can be achieved by using small interfering RNA (siRNA), 21-27 basepair, doublestranded RNAs, that once introduced into the cytoplasm of cells are highly efficient at gene knockdown at very low concentrations. 1 To date, numerous siRNA targets have been identified in cancer (reviewed in Putral et al. 2 ), and the downregulation of these genes in vitro using cationic lipidic vectors often results in reduced cancer cell proliferation. 1, 3 Despite the success in vitro, the in vivo delivery of siRNA has been the major obstacle to its progression into the clinic. Much effort has therefore been devoted to the development of suitable in vivo siRNA delivery systems for systemic use. Of these, the polyethylene glycol (PEG)ylated lipidic systems show promise, with early reports demonstrating their effectiveness in various cancer models. [4] [5] [6] The formulation procedures used in those studies, however, are labour intensive and require specialized equipments and skills. The resulting end products, being in aqueous states, are also not suitable for longterm storage. Prompted by these limitations, we recently reported on the development of a simple, yet efficient, hydration-of-freeze-dried-matrix (HFDM) method to formulate a vector that can protect siRNA from nuclease degradation and can accumulate in tumours after intravenous (i.v.) administration. 7 In addition to the simplicity of the preparation procedure, we also showed that these freeze-dried, lipidbased, formulations are highly stable even after storage at room temperatures for 1 month.
Here, we aim to further characterize these HFDM-formulated siRNA-loaded lipid particles and investigate their biological activities in cervical cancer mouse models. The recently developed prophylactic vaccines, though effective, will not decrease the number of new cervical cancer cases for another 15-20 years. 8 Therefore, there is still an urgent unmet clinical need for new treatments owing to the side effects and low response rate of current treatment strategies. 9 Moreover, the unique nature of the disease makes this an ideal model system for testing siRNA-based cancer therapies, as almost 100% of cases are caused by human papilloma virus (HPV) infection, thereby permitting exclusive targeting of cancer cell while leaving normal healthy tissue alone. This is due to the presence of two essential viral oncogenes, E6 and E7, in cervical cancer cells. These oncogenes disrupt p53 and pRB tumour suppression pathways in cells, and we and others have shown that targeting E6 and E7 by siRNA in vitro results in either cell senescence 1,10,11 or apoptosis. 12, 13 To date, the in vivo application has been limited to intratumoural injections with significant inhibition of tumour growth reported after single or multiple administrations. [14] [15] [16] [17] [18] Although these findings demonstrated the feasibility of using E6/7-targeted siRNA for cervical cancer treatment, the delivery strategies used in these studies have limited clinical application. We therefore aim to develop a suitable siRNA delivery system for the systemic administration of E6/7-targeted siRNA.
In this report, we first characterized the HFDM-formulated siRNA-loaded lipid particles in terms of stability and circulatory half-life. Importantly, we found that our designed particles are able to effectively deliver siRNA to tumours after i.v. administration, resulting in sequence-specific target gene knockdown. Using these particles, we subsequently investigated the effect of E6/7-targted siRNA in cervical cancer mouse models. The combinational use of siRNA and cisplatin was also examined both in vitro and in vivo. Overall, our results demonstrated the feasibility of using these HFDMformulated carriers to systematically administer E6/7-targeted siRNA for the treatment of cervical cancer. RESULTS E6/7 siRNA can efficiently reduce cell growth in E6/7-expressing TC-1 cells As the use of siRNA to reduce E6/7 gene expression in TC-1 cells has not been previously demonstrated, we first examined the effect of E6/7 knockdown in TC-1 cells using cationic dioleoyl trimethylammonium propane/dioleoylphosphatidylethanolamine (DOTAP/DOPE) liposomes. TC-1 cells were used in this experiment, as they are murine HPV16 E6/7-expressing cells, which allowed us to perform our subsequent animal experiments in immune-competent mice. Similar to our previously published data for HPV16 CaSki cells, 1 E6/7 siRNA treatment resulted in significant knockdown of E6/7 messenger RNA in TC-1 cells, as measured by quantitative polymerase chain reaction (PCR) ( Figure 1a ). As shown in Figure 1b , treatment with E6/7 siRNA, but not control siRNA, resulted in a significant decrease in cell viability (Po0.05). This is expected as continuous expression of E6/ 7 is required for the survival of TC-1 cells.
E6/7 siRNA-loaded liposomes prolonged survival of mice bearing lung metastasis tumours To assess the ability of E6/7 siRNA to inhibit TC-1 tumour growth in vivo, we administered cationic liposome-bound E6/7 siRNA intravenously to mice bearing cervical cancer lung metastasis. 19 We chose to use cationic liposomes to deliver siRNA in this experiment, as they have previously been shown to accumulate efficiently in lung tissues after i.v. administration. 20 In this experiment, mice were treated with lipoplexes containing 24 mg (1.2 mg kg À1 ) of E6/7 siRNA on days 1, 4 and 7 after tumour cell inoculation. We observed that the mice receiving the E6/7 siRNA treatment had a delayed onset of illness compared with those treated with vehicle only or with control siRNA (Figure 2a ). However, there was no survival advantage for E6/7 siRNA-treated mice compared with mice in the control groups. In contrast, when the treatment dosage was increased to 80 mg (4 mg kg À1 ) siRNA per mouse, E6/7 siRNA-treated mice had a significantly prolonged survival (Po0.005), with a median survival of 31 days compared with 19, 23.5 or 21 days for vehicle only, control siRNA or empty liposomes-treated groups, respectively (Figure 2b ). It must be noted, however, that although this demonstrated the feasibility of using E6/7 siRNA to treat cervical cancer metastasis, the application of this non-PEGylated liposomal delivery system likely limits to the first-pass organs and is not useful for solid tumours on other locations. We, therefore, subsequently evaluated the feasibility of delivering siRNA to solid cervical cancer tumours using our previously reported HFDM-formulated PEGylated lipidic system. 7 Serum stability and pharamacokinetic profiles of HFDM-formulated nucleic acid-loaded lipid particles We have previously established the ability of HFDM-formulated lipid particles to accumulate in subcutaneous tumours after systemic administration. 7 Here, we aimed to characterize these particles further via assessing their serum stability as well as their pharmacokinetic profile. As shown in Figure 3a , in contrast to the nonPEGylated lipoplexes in which large aggregates (43 mm) formed immediately after the addition of serum, the size of the HFDMformulated particles remained constant, even after prolonged incubation with serum at 37 1C (Figure 3b ). At the end of 24 h, the average size of HFDM-formulated particles was o200 nm, clearly demonstrating the suitability of these particles for systemic applications. Decreased TC-1 cell viability was observed after E6/7 siRNA treatment when delivered using DOTAP/DOPE liposomes. This decrease was not observed when cells were treated with control siRNA or empty liposomes. Tests were performed in triplicate 4 days after treatment using Cell Titre Glo assay. *Po0.05, significantly different to control siRNA treatment. All bars and error bars represent the mean value and the corresponding s.e.m.
To investigate the pharmacokinetic profile of these HFDMformulated particles, we monitored serum concentrations of entrapped fluorescein isothiocyanate-labelled oligonucleotides after i.v. administration over time. A rapid distribution phase was observed with the serum concentration dropping to 10% of the initial value within 2 h, indicating the efficient delivery of these oligonucleotides to various tissues (Figure 4a ). The concentration remained steady after 4 h, and the elimination half-life of our particles was 44 h. At 24 h, around 1.9% of the particles were still circulating in the bloodstream. The non-compartmental analysis showed an area under curve 0Àinfinity of 11.5 h ng ml À1 , clearance of 3.4 ml h À1 , steady state volume of distribution of 219.3 ml and mean residence time of 52 h.
In vivo gene knockdown efficiency and liver toxicity profile of HFDM-formulated lipid particles We next examined the tumour delivery efficiency of our siRNA-loaded HFDM-formulated lipid particles by assessing the level of target gene knockdown in tumours after i.v. administration. Green fluorescent protein (GFP), instead of E6/7, was chosen as the target gene as its expression level does not interfere with tumour cell survival, thereby allowing a more accurate determination of the knockdown efficiency of our delivery system. As shown in Figure 4b , GFP messenger RNA level was reduced by almost 50% in GFP-expressing tumours when mice were treated with two doses of particles loaded with 40 mg of siRNA directed against GFP. This knockdown was sequence-specific, as the lipid particles loaded with control siRNA did not result in a reduction in GFP messenger RNA.
Although this demonstrated the potential use of these particles in cancer therapy, one must also consider their safety profiles in vivo. As a significant amount of these particles accumulated in the liver after i.v. administration, 7 we performed an alanine transaminase enzyme test to detect any obvious adverse effect of these particles in the liver. The result showed that the administration of either 20 or 40 mg of siRNA-entrapped HFDM-formulated lipid particles gave no elevation of alanine transaminase enzyme activity at 24 h compared with vehicle-treated mice (Figure 4c ). HFDM-formulated E6/7 siRNA-loaded lipid particles are comparable to cisplatin for tumour reduction Having established that our siRNA-loaded PEGylated lipid particles can accumulate in subcutaneous tumours after i.v. administration and result in sequence-specific gene silencing, we next examined the effect of E6/7-targeted siRNA on tumour burden. We observed a 50% reduction of tumour growth rate for mice, which have been treated with three doses of HFDM-formulated E6/7 siRNA-loaded lipid particles compared with control groups (Po0.01) (Figure 5a ). This effect was not observed using the control siRNA, demonstrating the specificity of our siRNA. Importantly, this anti-tumour effect of E6/7 siRNA was found to be highly dependent on the use of our delivery system as naked E6/7 siRNA did not result in any reduction in tumour growth rate (Figure 5b ). Isotonic sucrose solution, used as the vehicle in our formulation, also did not have any effect on tumour growth compared with mock saline treatment (Figure 5b) . Overall, these results demonstrated the crucial role of our formulation in the successful systemic delivery of siRNA to tumours.
In order to compare the anti-tumour effect mediated by E6/7 siRNA with that of a standard chemotherapy drug commonly used in cervical cancer treatment, we treated mice bearing solid tumours with cisplatin. As shown in Figure 5c , both cisplatin and E6/7 siRNA resulted in around 50% reduction in tumour size on day 14 after 2-3 treatments. This result was promising as the cisplatin dose used in the experiment (50 mg m À2 , assuming body surface area of 36 cm 2 per mouse) is comparable to current clinical dosing.
Combination treatment of E6/7 siRNA and cisplatin in vitro and in vivo As monotherapy is often inadequate in cancer treatment, we investigated the potential combined use of E6/7 siRNA-entrapped lipid particles and cisplatin in cervical cancer treatment. We hypothesized that the combined treatment will have an additive effect in reducing tumour cell growth, thus, producing a more beneficial outcome. To test our hypothesis, we first examined the effect of this combined treatment in vitro with cells receiving E6/7 siRNA treatment first followed by cisplatin (Figure 6a ). Consistent with our finding in Figure 1b , treatment of cells with E6/7 siRNA resulted in around 50% reduction in cell viability. As expected, cell viability decreases with the increasing dose of cisplatin, with an IC 50 around 1.5 mM. There was, however, no obvious added benefit to combined cisplatin/siRNA treatment with similar doses of cisplatin required to produce 460% reduction in cell viability. As a few research groups have previously reported that either high E6/7 or low p53 status could render cells more sensitive to cisplatin treatment, 21, 22 we wondered if treating cells with cisplatin first (to induce DNA damage), followed by E6/7 siRNA (to release p53), would produce a better outcome. However, this reversed treatment order resulted in no improvement in terms of overall reduction in cell viability as shown in Figure 6b . These in vitro data suggested that treating E6/7-expressing cells with both E6/7 siRNA and cisplatin may not have a greater therapeutic benefit than either treatment alone. We subsequently confirmed this finding in vivo in which we treated the mice with three doses of E6/7 siRNA and two doses of cisplatin. We found that mice that received both treatments had similar levels of tumour growth inhibition compared with mice that received E6/7 siRNA treatment alone (Figure 6c ). This suggested that although the anti-tumour effect of E6/7 siRNA in vivo is comparable to that of cisplatin (Figure 5c ), there may be limited clinical value in this combined therapy.
DISCUSSION siRNAs have enormous potential in cancer treatment, but the development of an appropriate delivery system remains a crucial issue for their transition into the clinic. Owing to the complexity of currently available formulation procedures along with the product instability, we have developed a novel yet simple HFDM method to formulate siRNA-loaded particles in which the end products showed superior stability compared with the traditional formulations. 7 Results presented here clearly showed that the HFDM-formulated PEGylated lipidic particles can deliver siRNA to tumours efficiently after systemic administration and subsequently lead to sequence-specific antitumour effects in a cervical cancer mouse model. To our knowledge, this is the first paper that describes the systemic use of E6/7-targeted siRNA for treatment of cervical cancer.
As a proof-of-concept experiment, we first examined the effect of E6/7-targeted siRNA using cationic liposomes in a lung metastasis cervical cancer mouse model. Unlike the effect observed at low dosage (1.2 mg kg À1 per dose) (Figure 2a) , treatment of mice with 80 mg of E6/7 siRNA (4 mg kg À1 ) for four doses resulted in an average of 50% increase in their median survival compared with mice in the control groups (Figure 2b ). Although this is encouraging, it must be noted that the application site of this cationic delivery system would be restricted to first-pass organs, such as lungs or liver. [23] [24] [25] [26] Its application for treatment of tumours located elsewhere in the body would, thus, be limited unless extremely high doses were used, as is the case for the studies performed using cationic cardiolipin-based liposomes in subcutaneous breast or prostate cancer mouse models (15 mg kg À1 per day for 5 days). 27, 28 This, along with the possibility of embolism occurring after administration, would be likely to limit their clinical applications.
In contrast to these non-PEGylated lipid particles, our HFDMformulated PEGylated particles exhibit much more favourable characteristics for systemic application (Figure 3) . The circulatory half-life of these HFDM-formulated particles (T 1/2 lz440 h, Figure 4a ) was also found to be much longer than other formulations such as galactosylated cationic liposomes (T 1/2 lzo1 h) 23 or PEGylated polyplexes (T 1/2 lz¼1.5 h). 29 Using these HFDM-formulated particles, we demonstrated a 50% knockdown of the GFP target gene in tumours after systemic administration. This level of knockdown is comparable to many other studies using similar dosage, 5,30,31 although some have reported higher gene-silencing efficiency. 4, 32 However, it must be noted that the autograft TC-1 tumours used in our study, as opposed to the xenograft tumour models used in many other studies, [31] [32] [33] [34] would result in an underestimation of gene knockdown efficiency. This is due to the fact that the b-actin normalizing gene used in our assays would measure expression in all murine cells in the tumour and some of these would be host-derived, support cells that do not express GFP.
For siRNA to be used successfully as a cancer therapeutic agent, a fine balance between long-circulatory characteristic and the gene-silencing efficiency of the delivery particle is required. The importance of this was demonstrated in a recently published study on neutral lipid-coated wrapsome formulation. 6 Although their particles exhibited excellent pharamacokinetic profile, with 20% of the particles still circulating in the bloodstream at 24 h after administration, it was found that frequent administration of relatively high dose of siRNA (2.5-7.5 mg kg À1 , 7-10 doses) was required for effective gene-silencing and anti-tumour effect. In contrast to this, we required much lower doses of siRNA to produce a comparable outcome from our HFDM-formulated particles (2 mg kg À1 , three doses) (Figure 5a) . Indeed, our dosing is comparable to other PEGylated cationic systems such as stable nucleic acid-lipid particles (2 mg kg À1 , six doses) 4 or lipid-protamine-DNA particles (1.2 mg kg À1 , three doses). 5 As shown in Figure 5a , with three doses of treatments, there was a 50% decrease in tumour size for E6/7 siRNA-treated mice compared with mice in the control groups. This result is encouraging, as it was not only comparable to other studies, 4, 35, 36 but the anti-tumour effect was also similar to that achieved from cisplatin treatments using a clinically effective dosage (Figure 5c ). However, it is difficult to assess the knockdown of E6/7 in these tumours at the termination of the experiment, as the tumour cells that had taken up the E6/7 siRNA would likely have undergone apoptosis during the course of the experiment. Nevertheless, given the successful knockdown of the GFP target gene in tumours with the use of siGFP (Figure 4b) , it is reasonable to conclude that the anti-tumour effect observed following E6/7 siRNA treatments was at least partially contributed to by the specific knockdown of E6 and E7 in tumours. It must be noted, however, that siRNAs were administered into mice when tumour burden was small in our study. Although similar approaches have been used in other studies, 6, 32 it is important in the future to establish the optimal treatment time points and dosing schedule for our HFDM-formulated particles in this TC-1 tumour model. This can be achieved via performing a detailed pharmacokinetic and pharmacodynamic study on these particles, which will in turn improve our understanding of the clinical applicability of these siRNA-entrapped HFDM-formulated particles.
Although our work presents an advance in bringing siRNA forward as a cervical cancer therapeutic agent, monotherapy in cancer treatment is rarely sufficient to completely eradicate tumour cells in the body. This was evident from our tumour growth data where mice treated with either E6/7 siRNA or cisplatin still have tumours of significant size at the end point (Figure 5c ). Although increasing the dose of treatment may produce a better outcome, the combination approach presents as a much more attractive treatment option. However, contrary to our previously published data using E6/7 short hairpin RNA and cisplatin treatment in HeLa cells, 1 we found no added benefit for this combined approach with siRNA, regardless of the sequence of treatment (Figures 6a and b) . Although one may attribute this finding to the difference in duration of action between siRNA and short hairpin RNA, we also showed that several doses of siRNA treatment in vivo produced the same outcome (Figure 6c ). At this time, the exact mechanism behind this discrepancy between these two studies is not well understood. Despite this, our results, along with other in vitro studies performed using either HPV16 21 or HPV18-expressing cell lines, 22, 37 suggest that the knockdown of E6/7 may render these cancer cells more resistant to cisplatin treatment, possibly through p53 pathways. 21, 22 Although the combination therapy with other forms of chemotherapeutic agent, such as paclitaxel, may be beneficial, 21, 37 the study performed by Liu et al. 37 also indicated that the target sequence of the E6/7 siRNA is crucial for a successful outcome. Co-administration of siRNAs that target other genes that are also overexpressed in cervical cancer cells, such as epidermal growth factor receptor 5, 38 or Bcl-2, 39,40 may also be beneficial. Overall, the choice of siRNA target site, type and dose of chemotherapeutic agent used as well as treatment time points should all be taken into consideration when designing a better treatment regimen. Our development of effective and easy-to-prepare delivery particles for siRNA delivery will allow faster screening for in vivo application and enable rapid clinical translation.
In conclusion, this is the first paper describing the systemic use of E6/7 siRNA for treatment of cervical cancer. We showed for the first time that the hydration-of-freeze-dried-matrix (HFDM) method is a feasible way to formulate stable and efficient siRNA delivery particles, which result in knockdown of the target gene in tumours after systemic administration. Using these particles, we demonstrated a sequence-specific anti-tumour effect in a subcutaneous cervical cancer model. Although further studies are required to fully investigate the pharmacokinetic/pharmacodynamic profiles of our lipidic particles as well as their potential to induce cytokines after administration, the simplicity of preparation and the superior product stability are major advancements for the in vivo application of siRNA. Our technology offers an innovative approach for formulating siRNA as effective cancer therapeutics and can also be applied to other forms of cancer.
MATERIALS AND METHODS Materials
DOTAP and cholesterol were purchased from Sigma (St Louis, MO, USA). PEG 2000 -C16Ceramide conjugate was purchased from Avanti Polar Lipids (Alabaster, AL, USA) and DOPE was purchased from Northern Lipids (Vancouver, BC, Canada).
Control oligodeoxynucleotides with sense sequence of 5¢-GTCAGAAATAG AAACTGGTCATC-3¢ and antisense sequence of 5¢-GATGACCAGTTTCT ATTTCTGAC-3¢ were obtained from Invitrogen (Carlsbad, CA, USA). siRNA that targets both E6 and E7 (E6 and E7 are produced by the same transcriptional unit) (5¢-GCAACAGUUACUGCGACGUUU-3¢; 5¢-ACGUCGCAGUAA CUGUUGCUU-3¢) was obtained from Sigma-Aldrich in annealed form. Similarly, GFP-targeted siRNA (5¢-GCACGACUUCUUCAAGUCCUU-3¢; 5¢-GG ACUUGAAGAAGUCGUGCUU-3¢) and control siRNA (5¢-UUAUGCCGAU CGCGUCACAUU-3¢; 5¢-UGUGACGCGAUCGGCAUAAUU-3¢) were also purchased from Sigma-Aldrich.
TC-1 cells (murine C57B/6 lung epithelial cells transformed with HPV16 E6/7 and ras oncogenes) were obtained from TC Wu. 41 TC-1 GFP +ve cells were prepared according to the protocol described by Gu et al. 42 All cells were cultured and maintained in Dulbecco's Modified Eagle Media (DMEM; Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (Bovoge, Keilor East, VIC, Australia), 0.2% primocin (Invivogen, San Diego, CA, USA) and 2 mM L-glutamine (Invitrogen). Primocin was included in the media in order to prevent mycoplasma infection of the cells. All other chemicals and solvents used were of at least analytical grade.
Methods
Liposome formulations.
Non-PEGylated lipoplexes: DOTAP/DOPE (1:1 molar ratio) liposomes were prepared using the hydration of lipid film method as described previously. 43 Briefly, the required amount of lipids were dissolved in chloroform in a roundbottomed flask. Chloroform was then removed under low pressure using a rotary evaporator and a lyophilizer (ALPHA 1-2 LDplus, Martin Christ, Germany). Dried lipid film was hydrated using sterile 5% dextrose solution, with the final liposome concentration being 5 mM. Liposomes were subsequently extruded through 800 nmÂ5, 400 nmÂ5, 200 nmÂ5, 100 nmÂ5 and 50 nmÂ5 Nucleopore track-etched membranes (Whatman, Rydalmere, NSW, Australia) using Lipex extruder (Northern lipids) under nitrogen pressure of up to 500 psi. Extruded liposomes were left at room temperature for an hour before being stored at 4 1C. Liposomes were then complexed with the required amount of nucleic acids at an nitrogen:phosphate (N:P) ratio of 4 immediately before in vitro or in vivo studies.
HFDM-formulated nucleic acids-entrapped PEGylated lipid particles: Nucleic acid-entrapped PEGylated lipid particles were prepared as previously described. 7 Briefly, required amounts of DOTAP, cholesterol and PEG 2000 -C16Ceramide with or without DOPE were mixed with oligonucleotides or siRNA at an N:P ratio of 4 in a sucrose-containing water/tert-butanol (1:1 v/v) co-solvent system. DOTAP, cholesterol, DOPE and PEG 2000 -C16Ceramide with a molar ratio of 50:35:5:10 was used. The mixture was then snap-frozen and freeze-dried overnight. Freeze-dried matrix was then hydrated with sterile water immediately before use so that the final product contained 40 mg oligonucleotides or siRNA in 300 ml of isotonic sucrose solution.
In vitro studies.
siRNA transfection study and gene-knockdown analysis: TC-1 cells were seeded the day before the transfection experiment at a density of 100 000 cells per well in a six-well plate. DOTAP/DOPE liposomes were used to complex with HPV16 E6/7 siRNA and control siRNA at an N:P ratio of 4. A measure of 1 ml of 40 nM liposome-entrapped siRNA suspended in antibiotic-free complete DMEM was then added to each well. siRNAs were left on cells for 8 h, and cells were then incubated in primocin-containing DMEM culture media overnight at 37 1C.
After overnight incubation, total RNA was isolated from the cells using Trizol reagent (Invitrogen) according to the manufacturer's protocol. RNA (2 mg) was subsequently reverse-transcribed using Omniscript RT kit (Qiagen, Doncaster, VIC, Australia). Real-time PCR was performed on a Corbett RotorGene 3000 (Qiagen) using 0.1 ml of complementary DNA for each sample or the comparable amount of RNA extract with no addition of reverse transcriptase. A standard curve was also generated using 0.002-0.1 ml of complementary DNA per reaction, and all reactions were performed in 20 ml in triplicates. SYBR green (Applied Biosystems, Warrington, UK) was used to detect products and 200 nM of the following primers were used: E6/7 forward 5¢-AAGCAACAG TTACTGCGACGTG-3¢, E6/7 reverse 5¢-GCCCATTAACAGGTCTTCCAAA-3¢, b-actin forward 5¢-GCTACAGCTTCACCACCACA-3¢ and b-actin reverse 5¢-TCTCCAGGGAGGAAGAGGAT-3¢. PCR was set at 94 1C initially for 10 min, followed by 40 cycles of 95 1CÂ10 s, 60 1CÂ15 s and 72 1CÂ20 s. Results were analysed using Rotor-Gene 6000 series software (Qiagen). The relative amount of complementary DNA in each sample was normalized using b-actin and melt curve was used to verify specificity.
Cell viability assay: TC-1 cells were seeded in a 48-well plate at a seeding density of 3000 cells per well the day before the experiment. HPV16 E6/7 siRNA or control siRNA was complexed with DOTAP/DOPE liposomes at an N:P ratio of 4. A measure of 100 ml of 40nM siRNA-containing lipoplexes or empty liposomes suspended in OptiMem (Invitrogen) was then applied to each well. After 4 h of incubation, cells were then washed with phosphate-buffered saline (PBS) and were incubated in primocin-containing complete DMEM media for 4 days. All treatment was performed in triplicate (n¼3). Cell Titre Glo (Promega, Sydney, NSW, Australia) cell viability assay was subsequently performed according to the manufacturer's instructions.
For cisplatin experiments, cells were treated with siRNA and then cisplatin, or in the reverse order. siRNA was applied to cells as described above, and cells were treated with cisplatin (Sigma) at various concentrations from 0 to 50 mM in primocin-containing DMEM complete media (250 ml per well) for 24 h. Cell Titre Glo viability assay was performed at the end of day 4 and each treatment condition was performed in quadruplicate (n¼4).
Serum stability study. Non-PEGylated and HFDM-formulated PEGylated liposome formulations (100 ml), which contained 8 mg of siRNA, were incubated with 60 ml of non-heat inactivated fetal bovine serum at 37 1C. At various time points, samples were mixed with 4 ml of filtered distilled water, and the particle size was measured by photon correlation spectroscopy using a Zetasizer 3000 (Malvern Instruments, Malvern, UK). All measurements were carried out at room temperature, and three samples were measured at each time point (n¼3).
Animal studies. All animal experiments were approved by the University of Queensland Animal Ethics Committee and 2-month-old female C57B/6 mice (Perth, ARC) were used in all studies.
Pharmacokinetics study of HFDM-formulated particles: Mice were injected with HFDM-formulated lipid particles loaded with 40 mg of fluorescein isothiocyanate-labelled oligonucleotides. At different time points, around 50 ml of blood was collected from mice, and serum was isolated as previously described. 44 Fluorescein isothiocyanate oligonucleotdies were extracted from liposomes using the method described previously, 5 and the fluorescence intensity of the samples was measured using a Fluostar (BMG Labtech, Mornington, Victoria, Australia) plate reader at excitation and emission wavelengths of 485 and 520 nm, respectively. Fluorescein isothiocyanate-oligonucleotide concentration in each sample was calculated from a standard curve. Four to five mice were used in this experiment (n¼4-5), and the pharamacokinetic profile was analysed using non-compartmental methods using WinNonlin Professional (version 5.2). The key pharamacokinetic parameters provided from this analysis were area under curve, clearance, mean residence time and steady state volume of distribution, and terminal phase half-life was extrapolated from the last five time points.
In vivo gene-silencing experiment: Subcutaneous TC-1 GFP +ve tumours were established in mice as described above. On days 13 and 14 after tumour cell inoculation, mice were treated intravenously with either saline, HFDMformulated lipid particles containing 40 mg of either GFP-targeted siRNA, or control siRNA. Tumours were subsequently harvested on day 15, and RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's protocol.
RNA (2 mg) isolated from the tumours was reverse transcribed using an Omniscript RT kit (Qiagen). Real-time PCR analysis was performed as described earlier. The following primers were used: GFP forward 5¢-ACGTA AACGGCCACAAGTTC-3¢, GFP reverse 5¢-GGTCTTGTAGTTGCCGTCGT-3¢, b-actin forward 5¢-GCTACAGCTTCACCACCACA-3¢ and b-actin reverse 5¢-TCTCCAGGGAGGAAGAGGAT-3¢.
Liver toxicity study: Tumour-free mice were treated intravenously with either isotonic sucrose solution or HFDM-formulated lipid particles containing 20 or 40 mg of siRNA. Similar to other reported studies, 23, 33, 45, 46 blood was collected from mice at 24 h after the administration, and three mice were used for each treatment group (n¼3). Serum was then isolated from the samples as previously described and samples were stored at 4 1C before analysis. The assay was performed using alanine transaminase detection kit (Bioo Scientific, Austin, TX, USA) according to the manufacturer's protocol. All samples were tested in triplicate and alanine transaminase enzyme (12.5 ng ml À1 , Roche Diagnostics, Mannheim, Germany) was used as a positive control to test the validity of the assay.
In vivo tumour growth inhibition study. For the lung metastasis study, 0.5 million TC-1 cells suspended in 100 ml of sterile PBS were injected intravenously into each mouse. On days 1, 4, 7 and 11 after tumour cell injection, mice were treated with 5% dextrose solution, empty DOTAP/DOPE liposomes, liposome-complexed E6/7 siRNA or control siRNA. Liposome-siRNA formulations were prepared at a concentration no greater than 24 mg siRNA per 300 ml at an N:P ratio of 4 to prevent particle aggregations. For mice receiving 24 mg of siRNA per dose, the prepared formulation was administered intravenously into each mouse without further volume reduction step. When higher siRNA dosage was required, formulations were concentrated by centrifugation at 1000 g using a 100K Ultra-free centrifugation filter (Millipore, North Ryde, NSW, Australia). The final formulation contained 80 mg of siRNA in 200 ml and was administered to each mouse. Six to nine mice were used per treatment group, and the health of the mice was monitored over the course of the study. All mice were killed when they showed signs of illness, such as rough hair coat, hunched posture, laboured breathing or significant weight loss.
For the subcutaneous tumour study, one million TC-1 cells suspended in 100 ml of sterile PBS were injected subcutaneously into each mouse on the right abdominal side. On days 3, 7 and 10 after tumour cell inoculation, mice were treated with saline, vehicle only, naked E6/7 siRNA or HFDM-formulated lipid particles containing E6/7 siRNA or control siRNA. All formulations were prepared at an N:P ratio of 4, and 40 mg of siRNA was administered intravenously per dose. For the cisplatin experiment, 90 mg of cisplatin suspended in 200 ml PBS was administered into each mouse via intraperitoneal injection on days 8 and 11 after tumour cell inoculation. PBS was used as a negative control. Five to six mice were used per treatment group (n¼5-6), and tumour size was monitored using callipers during the course of the experiment.
Statistical analysis. All data were analysed using GraphPad Prism software (GraphPad software, La Jolla, CA, USA) and the Student's t-test was performed to assess the difference between treatment and control groups. For survival studies, the Mantel-Cox log-rank test was used.
